RxDoctor Payments Data

Jonathan Cross, MD

Neurology · Aventura, FLNPI 1336146927

Payments from drug & device makers

$1,008,965in general payments, 2019–2025

Across 897 payments — averaging $1124.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$554K
  • Vertex$278K
  • Ipsen Innovation$131K
  • AbbVie$10K
  • Eisai Inc.$9K
  • Argenx US, Inc.$6K
  • plus $20K from 54 others

What the payments were for

  • Consulting fees$18,34840%
  • Speaking & faculty fees$2,2505%
  • Travel & lodging$6,95215%
  • Food & beverage$18,37040%
  • Education$2060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly11$554,305
Vertex3$277,947
Ipsen Innovation143$131,301
AbbVie(2 entities)141$10,328
Eisai Inc.25$8,641
Argenx US, Inc.34$6,132
Biogen20$2,521
Pfizer50$2,357
Abbott14$2,150
UCB, Inc.37$2,019
Teva Pharmaceuticals USA, Inc.39$1,221
EMD Serono, Inc.28$1,174
AstraZeneca(2 entities)33$854
MDD US Operations, LLC27$786
Neurocrine Biosciences, Inc.43$665
Novartis11$579
Lundbeck LLC26$558
GE HealthCare10$508
SK Life Science, Inc.17$432
Lilly USA, LLC16$403
Otsuka America Pharmaceutical, Inc.17$397
Johnson & Johnson(2 entities)11$298
Acadia Pharmaceuticals Inc13$271
Tanabe Pharma America, Inc.10$256
Kyowa Kirin, Inc.5$216
Jazz Pharmaceuticals Inc.4$184
Acorda Therapeutics, Inc9$182
Upsher-smith Laboratories LLC9$176
Amneal Pharmaceuticals LLC9$173
Avion Pharmaceuticals9$151
Idorsia Pharmaceuticals US Inc6$139
Biohaven Pharmaceutical Holding Company Ltd.7$136
Novo Nordisk1$122
Sanofi2$114
Amgen(2 entities)5$102
CSL Behring4$96
Neurelis, Inc.4$88
Livanova USA, Inc.3$86
Merz Pharmaceuticals, LLC4$85
Axsome Therapeutics, Inc.3$82
Genentech USA, Inc.3$79
Sunovion Pharmaceuticals Inc.4$78
ANI Pharmaceuticals, Inc.2$63
Takeda Pharmaceuticals U.S.A., Inc.2$62
Vanda Pharmaceuticals Inc.2$47
Scilex Pharmaceuticals Inc.2$46
Averitas Pharma Inc.2$40
Octapharma USA, Inc.2$38
Alnylam Pharmaceuticals Inc.1$30
Banner Life Sciences, LLC2$30
Sumitomo Pharma America, Inc.1$24
Boston Scientific1$23
Greenwich Biosciences, Inc.1$21
Aquestive Therapeutics, Inc.1$21
Impel Pharmaceuticals Inc.1$20
GRT US Holding, Inc.1$19
Corium, LLC1$17
Life Molecular Imaging Ltd1$16
Almatica Pharma LLC1$16
Globus Medical1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,008,965 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$299,929
Medicare patients
724
Services billed
11,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5064$407,023
NuplazidPimavanserin Tartrate54$344,654
IngrezzaValbenazine Tosylate26$213,431
Radicava OrsEdaravone13$180,232
AustedoDeutetrabenazine13$164,722
Austedo XrDeutetrabenazine12$157,474
RytaryCarbidopa/Levodopa133$139,558
GocovriAmantadine Hcl21$74,657
Emgality PenGalcanezumab-Gnlm44$46,585
Aimovig AutoinjectorErenumab-Aooe27$36,965
UbrelvyUbrogepant25$30,893
NeuproRotigotine21$29,990
Emgality SyringeGalcanezumab-Gnlm17$26,219
RexultiBrexpiprazole13$20,797
BriviactBrivaracetam11$15,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$62$407,02364 claims
Acadia Pharmaceuticals IncNuplazid$271$344,65454 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,221$322,19625 claims
Neurocrine Biosciences, Inc.Ingrezza$665$213,43126 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$173$140,452146 claims
MDD US Operations, LLCGocovri$786$74,65721 claims
UCB, Inc.Neupro, Briviact$2,019$45,09732 claims
AbbVieUbrelvy$10,328$30,89325 claims
Otsuka America Pharmaceutical, Inc.Rexulti$397$20,79713 claims
Idorsia Pharmaceuticals US IncQuviviq$139$8,92018 claims
Almatica Pharma LLCSertraline Hcl$16$62555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →